Medtronic (NYSE:MDT) this week touted data for its Intrepid self-expanding transcatheter mitral valve replacement (TMVR) system.
Early data from 15 patients in an early feasibility study was presented as late-breaking clinical science at the 33rd Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation. The study evaluated patients with severe, symptomatic mitral valve regurgitation (MR), utilizing the transfemoral access route.
Get the full story at our sister site, Medical Tubing & Extrusion.